THE DEATH OF CANCER
In the last few years, exponential advances in biotechnology are on track to a true cure for cancer – a way to save millions of lives and improve the quality of life for countless more.
This is the story of one small Massachusetts company that is helping lead this revolution, and the incredible opportunity it presents for patients and investors alike.
Dear Fellow Investor,
Cancer is not just something that affects other people. Cancer has a way of hitting you right where you live, personally, one on one.
And I wouldn’t be surprised if you’ve been personally affected by it, like I have… watching friends or loved ones slowly wasting away from this nefarious disease.
Although we’ve been battling cancer since it was first described in ancient scrolls dating back to 1600 BC, it seems that we haven’t made that much headway in the last 3,600 years.
According to the World Health Organization, every year cancer kills more than 7.5 million people worldwide. That’s roughly the population of the entire state of Virginia.
And if the cancer doesn’t kill you, the standard treatment might.
Britain’s National Confidential Enquiry into Patient Outcome and Deaths conducted a study of 600 cancer patients who died within 30 days of chemotherapy treatment. The results are telling:
- 40% of the patients suffered significant poisoning as a result of the treatment.
- 25% of the deaths were either caused or hastened by the chemotherapy.
Even many doctors are critical of the traditional “slash-burn-poison” approach oncology has taken.
In 1991, Dr. Albert Braverman, professor of hematology and oncology at the State University of New York, Brooklyn, published an article in the renowned medical journal The Lancet, stating, “Many medical oncologists recommend chemotherapy for virtually any tumor, with a hopefulness undiscouraged by almost invariable failure.”
And a 2004 study by three Australian oncologists found that chemotherapy’s role in the five-year survival rate of cancer patients was a paltry 2.1%… in other words, instead of 62% of patients surviving five years after chemotherapy treatment, the number would be 60%.
Not much of a benefit, I’d say – especially considering the horrendous side effects of chemo and radiation.
But all that’s about to change...
Thanks to modern biotechnology, brand-new ways to fight cancer are now emerging at breakneck speed.
The good news is twofold: Finally, cancer’s days are numbered… and the new treatments have very little in common with the old “torture chamber” regimen that left so many patients scarred or disabled for life.
Chances are, you and I will not only get to see cancer’s defeat with our own eyes, we can help bring about its demise – and collect significant profits at the same time (more on that in a moment).
This is not pie-in-the-sky, wishful thinking.
This is about real, breakthrough technologies saving and improving the lives of millions of cancer victims. Here’s the story of one of them...
Susan’s battle with skin cancer
In my travels, I’ve had the privilege of meeting a great number of interesting people with amazing stories of challenges and successes.
I am actually guilty of seeking them out. Striking up conversations in hotel lobbies, airport van rides, and while waiting to board a flight – you never know where you’ll find an opportunity or just learn something incredible.
One evening, while stuck in an airport waiting for a formidable storm to pass, I happened to meet Susan, a woman who turned out to be among the grittiest cancer survivors I’ve ever met.
As our initially casual conversation about the “comfort” of lying on an airport floor eventually turned to technology and to my keen interest in medicine, I learned that Susan had not just been struck by cancer, she’d been standing toe to toe with the disease for most of her life.
I suspect in some ways I was drawn to this conversation because she wore the scars of that lifelong battle on her face.
From afar it appeared she had a number of worse than usual acne scars. But I learned in time that beneath her standard airport garb of a hooded university sweatshirt (her daughter was in her fourth year at William & Mary) and comfortable jeans, her fight with cancer had left her covered with scars, the result of countless small surgeries, skin grafts, and deformities from her affliction.
You see, Susan is one of an estimated 800,000 to 900,000 Americans who every year develop a form of cancer called basal cell carcinoma (BCC), which is typically found on the face and sun-exposed skin.
The good news for those with BCC is that it is considered “curable.” The bad news is that the only current “cure” requires surgery that can be both debilitating and disfiguring... especially to the face.
To make matters worse, Susan had a condition called Gorlin syndrome, which made her particularly susceptible to BCC.
Over a period of five years, Susan had endured over a dozen painful surgeries on her face alone and had over 100 cancerous skin lesions treated. At one point, her plastic surgeon had told her he was “running out of skin” he could patch her up with.
So this was not just a story of a war she fought and won (with the battle wounds to prove it), but of a mortal enemy she would have to face over and over again.
I see a lot of amazing medical technologies come and go in my line of work, and I’m keenly aware that the path to a publicly available treatment is excruciatingly long and rife with stumbling blocks.
Thus, I’m always leery of giving people false hope by telling them about the emerging technologies I see on a regular basis.
But after hearing Susan’s story, which was delivered with a tone of stoic resignation to the condition she would live with for the rest of her life, I felt the need to share with her what I am also going to share with you.
A new tactic in the war on cancer
For millions of folks like Susan, innovative cancer technology represents the hope of new weapons desperately needed to win the fight of their lives.
Fortunately, after basically treading water for a century, biotech breakthroughs are revolutionizing the way we treat cancer in much the same way other emerging technologies are changing conventional warfare.
Standard cancer treatment for the last 100 years were similar to a nuclear blast. Chemicals, surgery, and/or radiation attack the whole body like a nuclear bomb that wipes out everything in its wake. In both cases, the collateral damage is extreme.
Evolving to laser-guided weapons, the military has learned to focus its attack. There’s still damage and plenty of casualties, but less than before.
Similarly, the recent development of targeted radiation, microsurgery, and new chemicals still leaves plenty of carnage, but at least it attempts to inflict less harm.
The latest generation in conventional warfare is the electromagnetic pulse. These “EMP bombs” beat the enemy in a whole new way:
They precisely attack and wipe out only the electronic, communication, and networking capabilities.
Without the ability to communicate orders, the enemy is easily overtaken with minor damage to the infrastructure or physical casualties.
One small Massachusetts biotech company has developed a tiny pill that shuts down cancer in virtually the same way.
How do I know so much about this? Let me briefly introduce myself…
Extraordinary technology for
My name is Alex Daley; I’m the chief technology investment strategist for Casey Research and senior editor of Casey Extraordinary Technology (CET).
I’ve always been something of a tech geek, practically since I can remember. In third grade, I took my first computer apart and reassembled it, just for fun – and by the time I entered high school, I had a side business moonlighting as a programmer (which allowed me to purchase the first car I ever bought, a Nissan Altima, with my own money).
At the age of 20, when most of my friends spent their time playing Beer Pong, I became a professor of computer science and information technology. Granted, I may not have not have had quite as much fun in college as the average kid, but my nerdiness ultimately paid off. Some years later, I ended up working for and leading a division of Microsoft; finally, I worked directly under Bill Gates, turning R&D products into business profit centers.
One of my extracurricular interests was investing in promising tech stocks, and being right at the source of cutting-edge tech news greatly helped me in that regard… so much so that institutional investors started hiring me as a consultant.
But let’s not dwell on the past too much – what’s important is what I do now.
In a nutshell, I stake my living and reputation on helping investors earn extraordinary gains by finding well-run companies with great technology that the market has yet to discover. For example:
- 46% GAIN in 1 WEEK – I helped my subscribers make a quick 2,000%+ annualized gain buying and selling ArcSight Inc. (ARST), a leading global provider of IT security and compliance management solutions, just before it was acquired by HP.
- 43% GAIN – I recognized the growth of wireless communications and got my readers into InterDigital Inc (IDCC), a leader in technology solutions for use in digital cellular and wireless products and networks at $24.69. Five months later, I recommended selling for a tidy 43% gain.
- Up 218% – Recognizing the increasing threat of cyberterrorism, I suggested subscribers buy this technological leader in network security appliances and unified threat management when it was undervalued at $8.11. Within months, the rest of the market came to appreciate this company. Now readers are currently sitting on a gain of 218%.
I’m especially interested in companies with breakthrough technologies that can contribute to what our chairman Doug Casey calls “the ascent of man”... which, in my book, most certainly includes new ways to wipe out age-old, deadly diseases.
So let me tell you some more about the tiny Massachusetts-based company I discovered…
New “EMP Bomb” technology
kills cancer without
harming innocent cells
Research has shown that cells are controlled by communication networks called “signaling pathways” that transmit instructions for growth and mutation. One particular network, called the “hedgehog pathway,” is responsible for ordering many types of cancer cells to reproduce. Shut down that pathway, the communication stops, and the cancer dies.
GDC-0449 – this company’s revolutionary new small-molecule drug – does exactly that.
Like an army of tiny cancer-focused EMP bombs, GDC-0449 infiltrates cancerous cells where it shuts down GLI, the main communication molecule in the hedgehog pathway. Without the command to reproduce, the cancer cells simply die.
And unlike current treatments that non-discriminately attack all cells – and often make you sicker than the disease – GDC-0449 targets pathways primarily found in cancer cells. Surrounding cells and the rest of the body remain virtually unharmed.
The effectiveness of GDC-0449 has not gone unrecognized. This new treatment first passed Phase II trials with flying colors. And as of January 2012, it was officially approved by the FDA.
Which brings me back to Susan.
Susan and I have managed to stay in touch. And I’m happy to say that as a participant in the Phase II trials of GDC-0449, Susan is living proof that this breakthrough technology is truly a life-changer.
After years of a seemingly never-ending series of excisions, biopsies, and wide-margin lesion removals, Susan has finally received a miracle. What else could it be called when…
- Over the past 12 months, she hasn’t needed one single surgery.
- Not one new cancer has arisen.
- And nine of the cancerous lesions she started with have either significantly shrunk or disappeared altogether.
And she’s far from alone.
This could play a role in destroying up to 30% of all human cancers
The overall clinical benefit rate in the pivotal Phase II trial that preceded FDA approval showed that GDC-0449 shrank tumors or healed visible lesions, or prevented them from growing any further in an astonishing 75% of patients.
But even more astounding, Susan’s test group was comprised of only high-risk Gorlin patients for whom there is no other approved pharmacological treatment.
GDC-0449 slashed the development of new basal cell carcinomas (BCCs) by 96% while reducing the size of existing BCCs. And some patients achieved near-complete remission during this trial.
Think about how incredible this is.
Can you imagine what it would be like to go from ZERO options – no hope at all – to 96% effectiveness?
That’s the difference this breakthrough drug makes.
And BCC is just one of up to 30% of all human malignancies that are thought to depend on the hedgehog pathway for survival.
Soon GDC-0449 could become the drug of first choice for millions and millions of patients with a wide variety of cancers.
And that’s barely the tip of the iceberg for this amazing company
From Tiny Biotech
to $48 Billion in Investor Wealth
One evening in November 1972, following a long day of meetings at a scientific conference, molecular biologists Stanley Cohen of Stanford University and Herbert Boyer of the University of California, San Francisco (UCSF), chatted over corned beef and pastrami.
They ended up partnering to discover one of the most successful breakthroughs in the history of science: curing disease by synthesizing proteins.
Their discovery was still lab-bound when early in 1976 Robert Swanson, a 27-year-old venture capitalist with Kleiner, Perkins, Caufield & Byers (KP), persuaded Boyer to join him in starting a business in the Silicon Valley area that would use his newly patented techniques.
The two men called their company Genentech, as in GENetic ENgineering TECHnology.
In 1980, when Genentech first offered its stock to the public, the price shot from $35 to $89 per share in the first few minutes of trading – at the time the most rapid escalation in value in the history of Wall Street.
And KP’s pre-IPO investment of $200,000 instantly shot up more than 80,000% to a value of over $160 million. That’s like turning $1,000 into $800,000… virtually overnight.
While everyone obviously couldn’t get in pre-IPO, in the end Genentech still created more than $48 BILLION in investor wealth. Find the companies following that success model, and the gains could be astronomical.
With all its remarkable benefits, GDC-0449 still only targets one signaling pathway. But many cancers rely on a number of intersecting signaling pathways.
Enter CUDC-101, another new drug in this company’s pipeline.
CUDC-101 is designed to attack cancer cells at multiple points of intervention and cause complete and total disruption of the network.
It’s like shutting down the Internet with one bomb… the cell phone network with another… and landlines and cable with another.
This company’s breakthrough technologies are targeted… they’re safer… and they work. And they make the current standard of cancer care seem about as sophisticated as blood-letting or leeches.
Most importantly, they could save more than 11 million lives every year... and reward early investors with exponential gains as this company positions itself to go from zero to more than $100 billion in potential annual revenues.
Not only is this company a pioneer in proven cancer-beating technology… it also has the perfect mentor. It has partnered with the godfather of all biotech companies, Genentech.
Like this company, Genentech also started with nothing but a new technology – and it went on to become the largest and most successful biotech drug developer of the modern era.
When all was said and done, Genentech and its revolutionary new biotechnology went from zero income in 1976 to creating more than $48 billion worth of investor wealth by the time it was acquired by Swiss drug giant Roche in 2009.
Here’s what’s really amazing: the only product Genentech had – which wasn’t even FDA-approved at the time of their IPO – was a synthetic insulin that treats a rare form of diabetes you’ve probably never heard of.
Now imagine the potential gains from a company developing new biotechnologies focused
on beating cancer, the largest
and most difficult to treat
disease in the world
The epitome of that biotechnology is CUDC-101, which has already completed an FDA Phase I clinical trial in 2010, as well as a Phase Ib expansion trial in late 2011.
Now it's in the midst of another Phase I clinical trial that it expects to have completed later this year.
Of course, nothing is ever 100% certain when the FDA is involved, but this much is clear - this company. which is under the wing of Genentech, the pioneer in the field of biotechnology – has everything in place to make it a huge winner.
And if the FDA approves CUDC-101, the tiny company behind it (I’ll call it Cancer Killer #1 ) could easily reward investors with gains like those of Genentech.
But this isn't the only under-the-radar biotech firm I've targeted for huge potential gains...
- Cancer Killer #2 is developing biotechnology that harnesses our body’s own natural antibodies to identify and attack only cancer cells and inject them with a death agent. Phase II trials showed extraordinary promise, shrinking tumors in 97% of the patients and inducing complete remission in 34%. This company’s stock shot up 7.8% in one day when the FDA recently made its drug the first new treatment for Hodgkin’s lymphoma to be approved in more than 30 years. Some analysts predict sales of this drug could reach more than $400 million by 2015. With two more cancer-fighting drugs in its pipeline, there’s still time to get in on the coming extraordinary gains.
- Cancer Killer #3 has identified cellular messengers called RNAi that are very specific to every disease, including cancer. In short, RNAi controls which proteins are not made and which genetic traits do not develop. So, by controlling RNAi function, a host of diseases including cancer can be blocked from ever developing. Rather than creating hundreds of new drugs, this company builds the platform for attacking the RNAi of specific diseases. Then they partner with other companies, which match the specific RNAi platform with the appropriate drug to kill each disease. They’re building a broad base of licensing fees, milestone payments, and royalty income that offer the very real potential to double your money within the next 18 months... and continue growing as more and more platforms are developed.
- Cancer Killer #4 is a company perfectly positioned to use the RNAi platform technology of Cancer Killer #3 to fight and prevent disease. Its founders were the first to prove that RNAi could be used to prevent disease-causing genes from activating. This company is the technology leader in creating RNAi-based drugs that:
- can harness a single natural pathway making them potent and highly selective;
- can target virtually any protein, thereby attacking any illness;
- act “upstream, ” like “stopping a flood by turning off the faucet,” as compared with today’s medicines that simply “mop the floor”;
- simplify the process of identifying appropriate drug candidates, making discoveries more rapid and economical.
I estimate the prospective value of this stock to be six to seven times higher than the $12 it is now trading at... giving you a likely 375% gain if you get in now.
How to get the details on all four of these cancer biotech blockbusters
These are the biotech companies pioneering the most promising medical breakthroughs on the cusp of ridding the world of cancer forever.
These are the Genentechs of tomorrow – companies blazing new technologies – ready to earn handsome profits as the war on cancer stops the disease in its tracks.
For those who get in on the ground floor, this is a chance to not only earn substantial financial rewards but to do some extraordinary good in the world.
I realize that with all of the details I’ve shared on these four companies, if you spend some time and energy digging, you might find out who they are.
But knowing the company name is just the first step… you also need to know exactly when to buy and, more importantly, when to sell or take profits for maximum gains.
Fortunately, you don’t have to go it alone. Instead…
Imagine investing in Cancer Killer #1 so more people like Susan can get their lives back… and potentially turning every $1,000 you invest into $2,500 or more.
Imagine what could happen if you get in early on all four of the hottest, cancer-fighting biotech companies in the world.
Now imagine getting the inside scoop on all those companies absolutely free.
That’s what you will get in a special report I’ve just completed called The Curing Cancer Portfolio. I’m going to tell you how to get it in just a moment, but first I want to make sure you understand just how huge the current opportunities in biotech are.
Despite massive amounts of funding thrown at cancer for decades, the US Center for Disease Control predicts that new cases of cancer will double from 2002 rates, to 20 million cases per year by 2030.
Revolutionary new biotechnologies aimed at curing cancer place us on the brink of a completely new and growing market capable of generating billions of dollars worldwide.
And that’s just the current opportunity.
Billions of people around the world don’t even have access to health care yet, but the number who do is growing every day. As the world’s poorest populations gain wealth and access to medical treatment, the number of cancer cases treated around the world will grow exponentially… and so will the gains for early investors.
Biotechnology is the perfect market for speculators who want to make extraordinary gains
Right now biotechnology is one of the few sectors where market-smashing gains are not only still possible… they happen regularly. Consider these outlandish biotech successes:
- Enbrel, an arthritis treatment from Amgen, rakes in over $5 billion in sales a year.
- Same with Rituxan, Genentech’s novel treatment for non-Hodgkin’s lymphoma.
- Likewise with Humira, a treatment for autoimmune disorders like Crohn’s disease and rheumatoid arthritis.
- Avastin, a treatment for colon cancer used together with chemo, brought in $6.5 billion in 2010.
And there are dozens of other therapies producing a billion or more dollars a year in global sales.
Here’s the key: companies on the forefront of technology can take off even in a recession.
No matter what the market and economy are doing, a breakthrough technology is a breakthrough technology, and investors are rewarded accordingly.
Of course the risk is higher with a biotech trying to prove out a new treatment than with an established company and a well-proven therapy. But with elevated risk comes the potential for far greater returns, like these that would have turned every $5,000 invested into:
- $63,411 gain in one month (May 2009) on Vanda Pharmaceuticals (VNDA)
- $290,900 gain from March 2009 to May 2010 on Keryx Biopharmaceuticals (KERX)
- $341,875 gain from March 2009 to April 2010 on Human Genome Sciences (HGSI)
Warning: this is not for everyone
In the end, nine out of ten therapies submitted to the FDA will be rejected or withdrawn. Picking the technologies that will not only work but pass FDA muster is not for amateurs.
That’s why so many people suffer heavy losses investing in biotech, and why many others stay away from this potentially lucrative sector altogether.
While risk can never be eliminated, I’m more than happy to dive in and grab the biotech gold while others sit on the sidelines…because I’ve learned to minimize risk and increase the likelihood of hitting a home run through a process of painstaking research, an intimate familiarity with the underlying technology, and thorough understanding of the market dynamics.
For starters, I refuse to even consider any company that doesn’t pass my stringent five-part “tech screen”:
- Is the company capable of at least doubling its market share within the next 6 to 36 months?
- Has the company developed a technological breakthrough that withstands professional and regulatory scrutiny?
- Is the company run by experienced management with a proven history of turning new technologies into extraordinary profits?
- Does the company have a solid balance sheet so it can generate cash at minimum risk to ensure it can afford to bring its products to market?
- Is the company “under the radar” of institutional investors so we can get in undetected and eventually sell to them at maximum prices?
Fewer than 1 in 100 companies ever pass this test. And even if they do, there are still other factors to consider.
Next the company must flawlessly meet all of Casey Research’s timeless criteria ensuring it is rock-solid in every other way – including its people, financing, marketing, and price.
Then and only then do I select the one or two that have the best chance of making serious profits like these gains that Casey Extraordinary Technology subscribers hae recently realized.
- 147% gain on MAKO Surgical Corp. (MAKO), the technology leader in advanced robotic arms and orthopedic implants
- 70% gain on Ebix Inc. (EBIX), a high-tech software wizard serving the insurance industry
- 69% gain on Stratasys (SSYS), an innovative market leader that's positioned itself to reap vast rewards from the expansion of 3D printing
- 97% gain on iRobot (IRBT), whose government and industrial robots perform various missions – on land and in the sea – and whose home robots are revolutionizing the way people clean, inside and out
That’s exactly what you get with Casey Extraordinary Technology
Very few investors are paying much attention to these companies. They’re too small and too volatile for most, so you generally won’t hear about them on the news… or on the Internet… or on TV. That’s where I come in.
Casey Extraordinary Technology subscribers get in early, before these companies become the latest Wall Street darlings. Once the herd catches on and investors start bidding up the share price, we’re positioned and ready to take profits.
Every month in Casey Extraordinary Technology, I deliver right to your inbox the full, detailed, actionable information on the very best of these typically little-known companies with breakthrough innovations and rock-solid management from every field of technology, including:
- Aerospace and defense
- Medical devices and healthcare technology
- Software and Internet services
- Biotechnology and pharmaceuticals
- Computers and other electronics
- Information technologies
These are the companies with market- and life-changing technologies – like the newest cures for cancer – that are destined to become part of our everyday lives.
Every month I’ll take you deep inside these companies… even beyond the facts and figures. I’ll introduce you to the people committed to bringing these technologies to market. I’ll tell you not only when to buy but when it’s time to sell for maximum profit.
Speeding Past the “Law of Accelerating Returns”
The following chart, presented at the 2010 Consumer Genetics Conference in Boston, shows that the exponential pace of gene sequencing technology over the past decade is actually outpacing Moore’s Law.
When the Human Genome project – which I incidentally helped develop – began in 1990, critics pointed out that given the speed with which the genome could then be scanned, it would take thousands of years to finish the project.
Undaunted, project insiders believed the technology was emerging to complete the task in just 15 years. And they shocked the world when they finished the project in only 13 years… two full years ahead of schedule.
Today one of the companies in my technology portfolio, Pacific Biosciences of California (PACB) has perfected the technology to sequence and map any gene in less than one day. And basic questions can be answered for as little as $99 in 30 minutes.
From thousands of years… to 15 years… to 13 years… to 30 minutes. That’s exactly the exponential growth that makes technology such an amazing investment.
And that’s not all you get with a subscription to Casey Extraordinary Technology.
24/7 email alert: I stay on top of these companies and technologies as the market moves and opportunities change every day. As soon as breaking news occurs, I’ll send you a personal email alert giving you my up-to-the-minute advice and explanations regarding what’s happening… what’s likely to happen… and what action you should take.
Full resource library: The minute you sign up, you also get unlimited access to every back issue of CET – every article, every special strategy, every special report… everything we’ve ever published on technology investing.
Plus, my exclusive special report: When you accept a risk-free trial subscription to Casey Extraordinary Technology, I’ll send you my report The Curing Cancer Portfolio – free.
Remember, this report details everything you need to know about the four top new cancer technologies and the companies that develop them, all poised to return shareholders incredible gains.
Nothing else can give you the exponential growth technology can
According to American futurist Ray Kurzweil, technological change is exponential, not linear. Progress typically starts slowly – for example, advancing from 1 to 2, then 2 to 4. But it quickly accelerates, going from 4 to 10, 10 to 1,000 and so on.
Simply put, we won’t experience 100 years of progress in the 21st century – it will be the equivalent of 20,000 years of progress (at today’s rate).
Consider the tremendous exponential growth of computing power already in our lifetime.
Back in the 1970s, college students shared the same computer that that took up half of a building.
Today, the computer you carry around in your cell phone is a million times cheaper and a thousand times more powerful.
That’s a billion-fold increase in price performance in just 40 years.
Biotechnology is one of a wide range of technologies that are subject to this “Law of Accelerating Returns,” commonly known as “Moore’s Law.” It was named after former Intel Chairman Gordon Moore, who predicted the parabolic advance in the capacity of integrated circuits that makes your cell phone the technological powerhouse that it is.
And Casey Extraordinary Technology is uniquely qualified to bring you the very best of the best… the ones that will stretch Moore’s Law to the limits – the moment they become available.
Making extraordinary gains while finding the cure for cancer –
does it get any better?
Actually, it does – because, happily, I’m in the position to offer you a substantial discount to join the fold.
You see, normally a one-year subscription to Casey Extraordinary Technology costs $995. A reasonable fee, simply because the gains from just one of the stocks I mentioned above can cover your subscription and then some.
But if you agree to try my service today, I’d like to offer you an even better deal: Take Casey Extraordinary Technology for a test drive for just $749… a full 25% off the regular price.
The best part: you’ll lock in this lower price for as long as you remain a subscriber. And if you decide within the first three months that Casey Extraordinary Technology is not for you, I’ll refund every penny you paid – no questions asked. Of course you get to keep your free report, no matter what.
By joining today, you’ll get an entire year of my deeply researched advice and handpicked recommendations, plus receive your free report.
Then go ahead and use it all for 90 days without risk or worry –because your satisfaction is 100% guaranteed.
Please don’t miss out on
this extraordinary opportunity
Part of the beauty of the technology sector is that there’s always something new being developed that can improve the world… and make substantial profits for those who get in early. In my CET portfolio recently:
- A technology leader in the data-storage industry is up 59% in 5 months.
- A top vendor of network security applicanes is up 218% in 21 months.
- A manufacturer of cutting-edge devices that treat kidney disorders is up 107% in 23 months.
*as of February 2012
Soon I expect the companies that are curing cancer to outpace these technology winners… and make many people quite wealthy.
The question is: Will you be one of them?
I’ve told you all the essentials. Now it’s up to you.
Take Casey Extraordinary Technology for a risk-free “test drive” that will put you on the cutting edge of technology and extraordinary profits for many years to come.
Chief Technology Investment Strategist, Casey Research
P.S. Life-changing technologies come in all shapes and sizes. I just finished researching another exciting technology breakthrough that could revolutionize industry the way the invention of the cotton gin ushered in the industrial revolution. I’ve just completed another report with full details. I’ll also send you this report – that’s two technology-packed reports for you – free. So please respond today to take full advantage of this offer.